Netupitant/Palonosetron Efficacious for Prevention of N/V in Patients Receiving MEC or HEC

Share this content:
Netupitant/Palonosetron Efficacious for Prevention of N/V in Patients Receiving MEC or HEC
Netupitant/Palonosetron Efficacious for Prevention of N/V in Patients Receiving MEC or HEC

SAN ANTONIO – Netupitant/palonosetron (NEPA) is an efficacious and safe option for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC) and moderately emegotenic chemotherapy (MEC), a study presented at the 2016 San Antonio Breast Cancer Symposium (SABCS) has shown.1

5HT3 receptor antagonists in combination with NK-1 receptor antagonists and dexamethasone are recommended by international antiemesis guidelines for patients receiving HEC, including anthracycline-cyclophosphamide (AC)-containing regimens, and MEC.

“The 2016 published updated antiemetic guideline of the Multinational Association of Supportive Care in Cancer (MASCC) recommends the use of this triple combination also for carboplatin-based regimens,” said Jorg P. Schilling, MD, Gynaeco-oncology, Berlin, Germany. NEPA is a fixed combination capsule combining the long lasting NK-1 receptor antagonist netupitant and the 5HT3 receptor antagonist palonosetron.”

To evaluate the efficacy and safety of NEPA in patients receiving MEC or HEC, researchers in Germany conducted a noninterventional study of 2500 patients with cancer receiving care at more than 100 centers. Participants were receiving single-day or 2-day MEC or HEC.

To date, 1263 patients have been enrolled, of which 86.4% were women and 68.8% had breast cancer. The most common chemotherapy regimens were AC-based regimens, carboplatin-based regimens, and cisplatin-based regimens.

Results showed that in cycle 1, 88.5% achieved a complete response during the acute phase, 85.1% had a complete response in the delayed phase, and 79.3% had a complete response overall; in addition, 94%, 99%, and 93% had no emesis in cycle 1, respectively.

“NEPA was well tolerated with low-grade constipation being the most frequent treatment-related adverse event,” Dr Schilling added.

Researchers also found that 83.5% of patients rated the efficacy of NEPA as very good or good during cycle 1, while only 0.8% felt NEPA poorly controlled their nausea and vomiting.

“The efficacy as rated by physicians was similar during all 3 chemotherapy cycles with approximately 90% good or very good efficacy in each cycle,” said Dr Schilling.

“NEPA proved to be very effective in the prevention of chemotherapy-induced emesis and nausea in the acute and delayed phases of highly and moderately emetogenic, as well as AC-based, chemotherapy,” concluded Dr Schilling.


1. Schilling JP, Karthaus M, Klare P, et al. Non interventional study with netupitant/ palonosetron (NEPA) as CINV prophylaxis in highly or moderately emetogenic chemotherapy. Poster presented at: 2016 San Antonio Breast Cancer Symposium; December 6-10, 2016; San Antonio, TX.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs